hpski

Extreme FDA Trades: 20 Stocks Under 5 Bucks

Glad you mentioned Genta & CTIC. Both have had problems with FDA in the past. Genisense works in a subset of CLL patients - there was not a single leukemia doc sitting on the ODAC that gave it a thumbs down, and MM is a very difficult challenge, so delayed progression in a subset of patients with low LDH is progress . CTIC would like Pixantrone to be thought of as not adding to cumulative doxorubicin mediated cardiac muscle damage, but that data is probably not going to be significant. If ODAC blows off Genisense again, Genta is toast. I have to give Genta's Ray Warrell major league credit for staying with this and not abandoning ship - he could have gone back to the clinical setting at MSKCC or facsimile.